Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 4/20 | 0.46 |
| ▸ | NMT2 | O60551 | 3/20 | 0.46 |
| ▸ | FNTA | P49354 | 3/20 | 0.43 |
| ▸ | FNTB | P49356 | 3/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20756558 | 0.88 | NMT1 (0.56) | NMT1NMT2TLR2GLP1RNOD1 | |
| SCHEMBL22692635 | 0.87 | NMT2 (0.47) | NMT1NMT2FNTAFNTBPGGT1B | |
| SCHEMBL25773622 | 0.86 | NMT1 (0.51) | NMT1NMT2FNTAFNTBPGGT1B | |
| SCHEMBL24645937 | 0.83 | NMT2 (0.52) | NMT1NMT2TLR2GLP1RNOD1 | |
| SCHEMBL22692674 | 0.83 | NMT1 (0.52) | NMT1NMT2TLR2GLP1RNOD1 | |
| SCHEMBL20099252 | 0.82 | NMT2 (0.49) | NMT1NMT2TLR2GLP1RNOD1 | |
| SCHEMBL26923325 | 0.81 | NMT1 (0.50) | NMT1NMT2TLR2GLP1RNOD1 | |
| SCHEMBL20017023 | 0.81 | NMT1 (0.55) | NMT1NMT2FNTAFNTBPGGT1B | |
| SCHEMBL18879488 | 0.81 | TLR2 (0.48) | NMT1NMT2TLR2GLP1RNOD1 | |
| SCHEMBL22372369 | 0.79 | NMT2 (0.55) | NMT1NMT2TLR2GLP1RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | GALNT6, GALNT3, GALNT14 | NMT1 20/4885NMT2 36/4885FNTA 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.